The Anti-SARS-CoV-2 IgG Antibody Response of Participants Vaccinated with Different Vaccine Combination

Year 2023, Volume: 2 Issue: 1, 30 - 34, 18.04.2023

Murat Karameşe , Abdullah Gümüş

Abstract

Introduction: In current literature, there are lots of description about the new Coronavirus, named as SARS-CoV-2 by World Health Organization (WHO). Basically, SARS-CoV-2 has been identified as the etiological agent of COVID-19 disease which was reported a group of patients with pneumonia of unknown cause in Wuhan, China, in December 2019. In this work, our aim was to investigate the anti-S1 IgG response that occurs after different kinds and different doses of SARS-CoV-2 vaccines and the demographic characteristics of participants.
Materials and Methods: A total of 299 participants were included in this study to detect the Anti-SARS-CoV-2 IgG antibody. The only inclusion criteria for this study were being vaccinated minimum 2-doses of any SARS-CoV-2 vaccine. For detecting the antibody levels of participants, Anti-SARS-CoV-2 ELISA (IgG) test kit which applies a recombinant S1 subunit of the SARS-CoV-2 spike protein, enabling detection of IgG antibodies was used.
Results: Out of 299 individuals, 128 (42.8%) were male and 171 (57.2%) were female in our study. The mean age of individuals 35.11±8.13 (minimum: 19 and maximum: 59). The lowest antibody levels were belong to Group 2 and Group 3 (138.66±25.41, and 82.09±63.42 IU/ml, respectively), while the highest antibody levels were belong to Group 6 (239.35±18.73 IU/ml).
Discussion: According to our result, a significantly higher humoral immunogenicity of the SARS-CoV-2 BioNTech compared with the CoronaVac vaccine. A significant increase in serological response was achieved with the 3rd or 4th dose of vaccine; however, it had better to be vaccinated with BioNTech after 2nd dose of COVID-19 vaccine.

Keywords

SARS-CoV-2, COVID-19, Antibody response, CoronaVac, BioNTech

Supporting Institution

Kafkas University, Scientific Research Project Council (BAP)

Project Number

2022-TS-10

Thanks

The current study was financially supported by Kafkas University, Scientific Research Project Council (BAP), Kars, Turkey, under the project number 2022-TS-10.

References

• 1. Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J Med Virol. 2022;94(1):173-7.
• 2. Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases - Wuhan, China 2019-2020. China CDC Wkly. 2020;2(4):61-2.
• 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
• 4. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjw2cWgBhDYARIsALggUho-1UZZ8-nq5RpD1yJSJATo6ywV8GchTA7dME79slHbQsjc7mOEVPgaAodvEALw_wcB 2023 [
• 5. Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682-7.
• 6. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1):e0034121.
• 7. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643-50.
• 8. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-12.
• 9. Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune Response to SARS-CoV-2 Vaccines. Biomedicines. 2022;10(7).
• 10. Bayram A, Demirbakan H, Gunel Karadeniz P, Erdogan M, Kocer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560-7.
• 11. Barin B, Kasap U, Selcuk F, Volkan E, Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022;3(4):e274-e83.
• 12. Sağlık İ, Payaslıoğu M, Aydın Başkılıç R, Ener B, Ağca H, Tüzemen N, et al. Antibody Response (IgM and IgG) After Two Doses of Immunization Against SARS-CoV-2 and Comparison of Two Different Third Dose Administrations. Journal of Molecular Virology and Immunology. 2023;4(1):1-14.
• 13. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39-41.
• 14. Yavuz E, Gunal O, Basbulut E, Sen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol. 2022;94(8):3768-75.
• 15. Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2022;27(4):301-10.
• 16. Clavero R, Parra-Lucares A, Mendez-Valdes G, Villa E, Bravo K, Mondaca E, et al. Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. Vaccines (Basel). 2022;10(9).
• 17. Saure D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56-63.
• 18. Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med. 2022;20(1):216.
• 19. Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, et al. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. J Clin Virol. 2022;156:105273.